Dipraglurant, an investigational oral therapy from Addex Therapeutics, eased motor and nonmotor symptoms associated with Parkinson’s disease in rodent models, a study showed. Along with being rapidly absorbed in the bloodstream, dipraglurant demonstrated anti-parkinsonian effects and reduced behaviors associated with anxiety, depression, and obsessive-compulsive disorder in mice and…
News
AT-04 and AT-07, experimental therapies Attralus is developing to treat Parkinson’s disease and other neurodegenerative disorders, are able to potently bind to several proteins that form toxic clumps in these conditions. That’s according to new data shared at the AD/PD 2023-International Conference on Alzheimer’s and Parkinson’s Diseases and…
Older age at the onset of disease, high blood pressure, poor cognitive and motor function, and mutations in the APOE gene are risk factors of future cognitive impairment in newly diagnosed Parkinson’s disease, a study showed. The combination of these factors was able to more accurately predict which patients…
Parkinson’s Awareness Month in April is a global opportunity to bring attention to the progressive neurodegenerative disease, as well as to educate communities about available resources, according to patients and advocates. Since 1997, World Parkinson’s Day has been celebrated on April 11. It commemorates the birth of James Parkinson, the…
Parkinson’s disease patients carrying severe variants in the GBA gene, a known genetic risk factor, experience faster motor and cognitive decline than those without such mutations, a Chinese study shows. Faster motor function decline was primarily driven by worsening bradykinesia (slow movements) and axial impairment (walking, posture, and balance…
One year of treatment with Anavex 2-73 (blarcamesine) safely led to a reduction in symptom severity for 20 people with Parkinson’s disease dementia in an extension study of the Phase 2 ANAVEX 2-73-PDD-001 trial. This finding was in sharp contrast with the worsening of symptoms observed in the months that…
Wren Therapeutics has developed oral small molecules that suppress the production of toxic alpha-synuclein protein forms in cellular and mouse models used to study Parkinson’s disease. The potential first-in-class molecules were designed with Wren’s technology platform to hinder processes involved in the generation of alpha-synuclein oligomers, the…
Blocking the activity of the synuclein nitrase enzyme reduced the levels of toxic clumps of the alpha-synuclein protein and lessened paralysis in mouse models of Parkinson’s disease, according to new data from Nitrase Therapeutics. Formation of toxic aggregates of alpha-synuclein is a hallmark of Parkinson’s and “has been…
PharmaTher Holdings has received guidance from the U.S. Food and Drug Administration (FDA) on the late-stage clinical development of ketamine for levodopa-induced dyskinesia, or uncontrolled movements, in people with Parkinson’s disease. “We are satisfied with the feedback we received from the Type C meeting with the FDA, which lays…
A science team at Merck (known as MSD outside North America) is the winner of an $8.5 million competition to develop an imaging technology capable of visualizing alpha-synuclein protein in the brains of people living with Parkinson’s disease, the contest’s organizer, The Michael J. Fox Foundation for Parkinson’s…
Recent Posts
- Pushing forward this Parkinson’s Awareness Month with boldness, grace
- Personalized DBS for Parkinson’s may result from brain study in China
- Fecal transplants ease motor symptoms in early Parkinson’s: Study
- ‘Moving Day, A Walk for Parkinson’s’ marks 15th year with events across US
- Choosing when to share a Parkinson’s diagnosis isn’t one-size-fits-all